These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 29180132)

  • 1. The effect of intravitreal cholinergic drugs on motor control.
    Willis GL; Freelance CB
    Behav Brain Res; 2018 Feb; 339():232-238. PubMed ID: 29180132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A; Simon N; Vidal J; Bruguerolle B
    Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular microinjections repair experimental Parkinson's disease.
    Willis GL
    Brain Res; 2008 Jun; 1217():119-31. PubMed ID: 18502399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Willis GL
    Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical Systems of the Retina Involved in the Control of Movement.
    Willis GL; Freelance CB
    Front Neurol; 2017; 8():324. PubMed ID: 28725212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldrin-induced locomotor activity: possible involvement of the central GABAergic-cholinergic-dopaminergic interaction.
    Jamaluddin S; Poddar MK
    Pol J Pharmacol; 2001; 53(1):21-30. PubMed ID: 11785907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease.
    Li SY; Wang YL; Liu WW; Lyu DJ; Wang F; Mao CJ; Yang YP; Hu LF; Liu CF
    Chin Med J (Engl); 2017 May; 130(9):1085-1092. PubMed ID: 28469105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
    Smith ES; Hardy GA; Schallert T; Lee HJ
    Neuroscience; 2016 Nov; 337():295-305. PubMed ID: 27664460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process.
    Willis GL
    Rev Neurosci; 2008; 19(4-5):245-316. PubMed ID: 19145986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.
    Navailles S; Bioulac B; Gross C; De Deurwaerdère P
    Neurobiol Dis; 2011 Feb; 41(2):585-90. PubMed ID: 21092759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
    Cole DG; Growdon JH; DiFiglia M
    Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
    J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.